Takeda announced that Omontys is now available in the US.
In March 2012, Omontys (peginesatide) was approved by the FDA for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. This marks the entry of the only once-a-month erythropoiesis-stimulating agent for anemia available to dialysis patients in the US. The product is to be co-marketed by Affymax and Takeda who will be responsible for the distribution of the product.
To order Omontys, providers can contact their group purchasing organizations, specialty distributors or call 1-855-Gomontys (1-855-466-6689)
Takeda prepares to announce the results of its 2011 fiscal year on May 11, 2012.
In March 2012, Omontys (peginesatide) was approved by the FDA for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. This marks the entry of the only once-a-month erythropoiesis-stimulating agent for anemia available to dialysis patients in the US. The product is to be co-marketed by Affymax and Takeda who will be responsible for the distribution of the product.
To order Omontys, providers can contact their group purchasing organizations, specialty distributors or call 1-855-Gomontys (1-855-466-6689)
Takeda prepares to announce the results of its 2011 fiscal year on May 11, 2012.
No comments:
Post a Comment